Yasmin Contraindications / Precautions
- adrenal insufficiency
- breast cancer
- cerebrovascular disease
- cervical cancer
- coronary artery disease
- coronary thrombosis
- endometrial cancer
- hepatic disease
- hepatocellular cancer
- hyperkalemia
- jaundice
- myocardial infarction
- pregnancy
- renal failure
- renal impairment
- stroke
- thromboembolic disease
- thrombophlebitis
- vaginal bleeding
- vaginal cancer
- valvular heart disease
- acquired immunodeficiency syndrome (AIDS)
- breast-feeding
- children
- cholestasis
- contact lenses
- depression
- diabetes mellitus
- electrolyte imbalance
- gallbladder disease
- headache
- human immunodeficiency virus (HIV) infection
- hypercalcemia
- hypercholesterolemia
- hyperlipidemia
- hypertension
- hypertriglyceridemia
- hypothyroidism
- incomplete abortion
- menstrual irregularity
- migraine
- obesity
- obstetric delivery
- ocular disease
- porphyria
- renal disease
- surgery
- systemic lupus erythematosus (SLE)
- thyroid disease
- tobacco smoking
- uterine leiomyomata
Yasmin (Drospirenone; Ethinyl Estradiol) Contraindications / Precautions
This product does not protect against human immunodeficiency virus (HIV) infection or other sexually transmitted diseases. Conversely, patients with known HIV infection or acquired immunodeficiency syndrome (AIDS) should be aware that the use of this oral hormonal contraceptive (OC) will not prevent the transmission of HIV or other sexually-transmitted diseases to their partner(s).
Drospirenone has antimineralocorticoid activity and may increase serum potassium. Because of the antimineralocorticoid activity, drospirenone may predispose certain patients to hyperkalemia or impaired adrenal function; thus drospirenone; ethinyl estradiol is contraindicated in patients with renal impairment, renal failure, or adrenal insufficiency. The use of potassium-sparing medications concurrently with drospirenone may predispose to this electrolyte imbalance; females taking such medications should have their potassium level checked during the first treatment cycle with drospirenone; ethinyl estradiol, and as clinically indicated thereafter.
Oral contraceptives are contraindicated during pregnancy and are labeled FDA pregnancy risk category X. Increased risk of a wide variety of fetal abnormalities, including modified development of sexual organs, cardiovascular anomalies and limb defects, have been reported following the use of estrogens or synthetic progestins alone in pregnant women. In addition, OC use may change folate metabolism, and women who discontinue OCs to pursue pregnancy should preferably wait 3 months for folate concentrations to normalize if possible. Folate supplementation should be given once pregnant to reduce the incidence of neural tube defects. Recent studies have found no increased risk of birth defects among women who have inadvertently continued to take birth control pills after they unknowingly became pregnant. In any patient in whom pregnancy is suspected, pregnancy should be ruled out before continuing oral contraceptive use.
Because of an increased risk of thromboembolism in the immediate post-partum period, combination hormonal OCs should be used no earlier than 4 weeks following obstetric delivery, provided the mother is not breast-feeding. Because estrogens and progestins distribute to breast milk in small quantities and may interfere with the quality and quantity of lactation, combination OCs should be avoided if possible while breast-feeding. In general, other forms of contraception are preferred until the infant has been weaned. After oral administration, roughly 0.02% of a drospirenone dose was excreted into the breast milk of postpartum women within 24 hours. This results in a maximal daily drospirenone dose of roughly 3 mcg to the infant.
Because of the antimineralocorticoid activity, the progestin drospirenone is contraindicated in patients with hepatic disease. Furthermore, combination estrogen-progestin oral contraceptives are classified as carcinogenic to humans in the development of hepatic cancer by the World Health Organization, International Agency for Research on Cancer (WHO IARC). Because of the association with cholestasis and hepatic neoplasms, estrogens are contraindicated in the presence of hepatocellular cancer, hepatic adenoma, or markedly impaired liver function (e.g., uncompensated cirrhosis). Those with a history of cholestatic jaundice/pruritus of pregnancy or jaundice from prior hormonal contraceptives should not use drospirenone; ethinyl estradiol. In general, estrogens-progestins are also relatively contraindicated in patients with pre-existing gallbladder disease and acute or intermittent porphyria.
Preliminary studies have suggested that obesity may be a risk factor for OC failure, particularly with the predominantly lower-dose (i.e., < 50 mcg/day) estrogen formulations available; more studies are needed. Also, pre-existing morbid obesity can be one factor that may increase cardiovascular or thromboembolic risks associated with combination hormonal contraceptive use in selected individuals.
Although the effects appear to be minimal in most non-diabetic patients receiving hormone therapy with estrogen-progestin combinations, altered glucose tolerance secondary to decreased insulin sensitivity has been reported. Patients with hyperglycemia or diabetes mellitus should be observed for changes in glucose tolerance when initiating or discontinuing therapy. Because of the increased potential for embolic risk, combined OCs are contraindicated in patients with diabetes with vascular involvement.
Estrogens generally have a favorable effect on blood lipids, and reduce LDL and increase HDL cholesterol concentrations. Progestins, however, may attenuate some of these effects by raising LDL and may make control of pre-existing hyperlipidemia more difficult in some women. Serum triglycerides increase with estrogen administration. A small proportion of women may have persistent hypertriglyceridemia while using combined hormonal contraceptives.
Hormonal contraceptive agents have been associated with thromboembolic disease such as deep venous thrombosis (DVT). A positive relationship between estrogen dosage and thromboembolic disease has been demonstrated. Products containing 50-mcg ethinyl estradiol should not be used unless medically indicated. In addition, certain progestins may increase thromboembolic risk. Because tobacco smoking increases the risk of DVT, myocardial infarction, stroke and other thromboembolic disease, estrogen-progestin contraceptives should be used cautiously, if at all, in smokers. Risk is especially high for female smokers 35 years of age or older or those who smoke >= 15 cigarettes per day. Women receiving OCs should be advised not to smoke. Pre-existing high blood pressure, renal disease, hypercholesterolemia, hyperlipidemia, morbid obesity or diabetes may increase risks. Hormonal contraceptive agents are contraindicated in patients with a current or past history of stroke, cerebrovascular disease, coronary artery disease, coronary thrombosis, thrombophlebitis, thromboembolic disease or valvular heart disease with complications. Because of their association with elevations in blood pressure, oral contraceptives should be used cautiously in patients with mild to moderate hypertension or kidney disease; use is contraindicated in patients with severe hypertension. Blood pressure should be monitored closely in these individuals. Any significant increase in blood pressure may require discontinuation of the OC. OCs may also cause fluid retention, and patients predisposed to complications from edema should be closely monitored.
Approximately 85% of patients diagnosed with systemic lupus erythematosus (SLE) are females, giving support to the notion that hormonal influences contribute to the pathophysiology of SLE. Accordingly, oral contraceptive (OC) use has been reported to induce, unmask, and exacerbate lupus; case reports and other anecdotal data indicate that a temporal relationship between OC use and lupus flares exist. However, several retrospective studies dispute a relationship between OCs causing or exacerbating lupus, and a large prospective, randomized clinical trial (SELENA) evaluating the safety of estrogen therapy (both as OCs and hormone replacement therapy in postmenopausal women) has been completed and is being analyzed. Determining the risk of OC use in SLE patients is important as women with lupus benefit from OCs; not only do they offer reliable birth control, but they also possibly protect patients requiring chronic corticosteroid therapy from bone fractures and osteoporosis. Women with hypercoagulable states are at increased risk of venous thromboembolism when taking OCs; given the increased prevalence of hypercoagulable states in patients with SLE (in particular antiphospholipid antibodies and lupus anticoagulant), presence of a hypercoagulable state should be determined prior to initiation of OCs in this population. OCs should be avoided in SLE patients with a history of venous or arterial thrombosis or the presence of a hypercoagulable state. If OCs are initiated in SLE patients without hypercoagulable states, low-dose estrogen contraceptives (i.e., 30—35 mcg of ethinyl estradiol or equivalent) should be used and consideration to a progestin-only contraceptive should be given. In addition, it may be prudent to avoid OC therapy in patients with unstable or severe SLE or a history of SLE exacerbation with estrogen therapy until more data regarding the use of OCs in this population are available.
Patients undergoing elective surgery of a type associated with an increased risk of thromboembolism should stop combination hormonal contraceptives at least 4 weeks prior and 2 weeks after surgery. Combination hormonal contraceptives should also be stopped during and after any prolonged immobilization.
The onset or exacerbation of migraine or the development of headache with a new pattern that is recurrent, persistent or severe requires evaluation of the cause. Do not use combined hormonal oral contraceptives in those patients with headaches that include focal neurologic symptoms.
Mood disorders, like depression, may be aggravated in women taking exogenous hormones. Women with a history of depression may need special monitoring. Low-dose oral contraceptive products may have minimal effect on depressive symptoms. If significant depression occurs, the oral contraceptive should be discontinued.
Estrogens can increase the curvature of the cornea and may lead to intolerance of contact lenses. There have been clinical case reports of retinal thrombosis. Any change in vision or visual acuity should be examined by an ophthalmologist. Hormonal contraceptive agents should be discontinued in patients developing any unexplained visual disturbance or ocular disease.
The safety and efficacy of hormonal contraceptive products have only been established in females of reproductive age. Safety and efficacy of hormonal birth control are expected to be the same for postpubertal children < 16 years of age and for users >= 16 years old. Use of hormonal contraceptives in female children before menarche is not indicated.
Estrogens are generally contraindicated in patients with pre-existing breast cancer. The issue of prescribing combination hormonal contraceptives to women with a family history of breast cancer is controversial. In all patients, individual risk versus benefit asessment must be performed. Several large, well designed observational studies have provided rconflicting data regarding the risk of breast cancer with OC use. A landmark case control study, the Cancer and Steroid Hormone (CASH) study, was published in 1986 and reported a lack of association between OC use and breast cancer. However, in 1996, the results of a meta-analysis of 54 studies specifically looking at the effects of OCs in more than 150,000 women were published. A small, statistically significant risk for breast carcinoma existed for women taking OCs; the risk steadily diminished to baseline over 10 years following discontinuation. The breast cancers diagnosed in this study tended to be localized and less advanced. The value of the data from this meta-analysis was limited because of variances in study designs and patient follow up; however, the controversy over steroid hormone exposure and the risk of breast cancer continued. In 2002, the results of the Women’s CARE trial were reported. No associations between past or present use of OCs and breast cancer were observed; the study included 4575 women with breast cancer and 4682 controls between the ages of 35—64 years old; > 75% of the study participants had used OCs. After a thorough review of the available data, the WHO IARC has classified combination estrogen-progestin oral contraceptives as carcinogenic to humans; the agency indicates that OCs slightly increase the risk of breast cancer in current and recent users (i.e., within 10 years); however, 10 years after cessation, the risk of breast cancer appears to be similar to that in those patient that have never used OCs. The studies noted evaluated the use of OCs for the purpose of contraception, and may not apply to the use of combination hormonal contraceptives as hormone-replacement therapy alternatives in the perimenopausal woman (i.e., use of hormones later in life).
Estrogen-progestin combinations are not recommended in patients with hypercalcemia associated with tumors or metabolic bone disease because estrogens influence the metabolism of calcium and phosphorus.
Oral contraceptives are contraindicated in patients with pre-existing cervical cancer. An association between oral contraceptive use and cervical cancer has been demonstrated. Generally, the risk of invasive cervical cancer in women who use oral contraceptives is greatest in women who take OCs for more than 5 years. Accordingly, the WHO IARC has classified combination estrogen-progestin oral contraceptives as a carcinogen in the development of cervical cancer. Evaluation of patients via cervical cytology screening should be performed prior to OC use.
Since 1970, at least 35 epidemiological studies have examined the association of exogenous estrogen and an increased incidence of cancer of the endometrium. A recent meta-analysis of 10 studies indicates a significant trend in decreasing endometrial and ovarian carcinoma risk with increasing duration of combined OC use. The beneficial effects of the OCs in this regard may persist for 15 years after OC use ceases. However, in those women with known endometrial cancer or other estrogen-dependent tumors (e.g., vaginal cancer), estrogen-containing OCs are contraindicated, as administration of exogenous estrogen may worsen the condition.
Hormonal contraceptive agents are relatively contraindicated in women with undiagnosed menstrual irregularity including undiagnosed vaginal bleeding, or incomplete abortion. A relative contraindication also exists for uterine leiomyomata (fibroids) because the drug can cause the fibroids to increase in size. Menstrual irregularity may occur with OC use, especially in the first few months of treatment and patients should be advised of this effect.
Use estrogens with caution in patients with thyroid disease, particularly hypothyroidism. Estrogens can increase thyroid-binding globulin (TBG) levels. Patients with normal thyroid function can compensate for the increased TBG by making more thyroid hormone, thus maintaining free T4 and T3 serum concentrations in the normal range. Patients dependent on thyroid hormone replacement therapy who are also receiving estrogens may require increased doses of their thyroid replacement therapy. These patients should have their thyroid function monitored in order to maintain their free thyroid hormone levels in an acceptable range.
[ Last revised: 9/15/2005 4:38:00 PM ]
Related entries
Monthly Archives
Syndicate
Allergies
